Skip to main content
. 2021 May 31;11:11350. doi: 10.1038/s41598-021-90879-z

Figure 3.

Figure 3

Changes in outcome measures in the group treated with dapagliflozin and protein-rich formula diet (P-FD) and the group treated with dapagliflozin and fat-rich formula diet (F-FD). (A) Change in HbA1c, (B) change in fasting insulin, (C) change in homeostasis model assessment of beta cell function (HOMA-beta), (D) change in skeletal muscle mass, (E) change in body fat mass. Data are presented as mean ± SD.